Edition:
United States

Leap Therapeutics Inc (LPTX.OQ)

LPTX.OQ on NASDAQ Stock Exchange Global Market

8.61USD
22 May 2018
Change (% chg)

$0.16 (+1.89%)
Prev Close
$8.45
Open
$8.61
Day's High
$8.61
Day's Low
$8.61
Volume
103
Avg. Vol
20,385
52-wk High
$10.25
52-wk Low
$4.94

Chart for

About

Leap Therapeutics, Inc., formerly HealthCare Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company. The Company engages in acquiring and developing therapeutics in cancer biology. Its lead product candidates for use in clinical trials include TRX518 and DKN-01. DKN-01 is a monoclonal antibody targeting Dickkopf-re... (more)

Overall

Beta: --
Market Cap(Mil.): $119.66
Shares Outstanding(Mil.): 14.70
Dividend: --
Yield (%): --

Financials

  LPTX.OQ Industry Sector
P/E (TTM): -- 222.84 32.59
EPS (TTM): -3.96 -- --
ROI: -148.17 -7.75 12.60
ROE: -209.63 -10.55 14.49

BRIEF-Leap Therapeutics Files For Mixed Shelf Of Up To $100 Mln

* LEAP THERAPEUTICS INC FILES FOR MIXED SHELF OF UP TO $100 MILLION - SEC FILING ‍​ Source text : (http://bit.ly/2I0IyH4) Further company coverage:

Mar 02 2018

BRIEF-Leap Therapeutics Reports Qtrly Loss Per Share Of $0.65

* LEAP THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND ANNOUNCES DATE OF ITS ANNUAL MEETING OF STOCKHOLDERS

Feb 23 2018

BRIEF-Leap Therapeutics Announces First Patient Dosed With TRX518 Combination Therapy

* LEAP THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED WITH TRX518 COMBINATION THERAPY IN ADVANCED SOLID TUMORS TRIAL Source text for Eikon: Further company coverage:

Jan 16 2018

BRIEF-Leap Therapeutics Files For Resale Of Up To 3.73 Mln Shares Of Co's Common Stock By Selling Stockholders

* LEAP THERAPEUTICS INC FILES FOR RESALE OF UP TO 3.73 MILLION SHARES OF CO'S COMMON STOCK BY THE SELLING STOCKHOLDERS - SEC FILING Source text: (http://bit.ly/2jdjIfs) Further company coverage:

Dec 08 2017

Earnings vs. Estimates